Tiziana Life Sciences – Grant of Options, Director Dealings August 26, 2020 – Posted in: Tiziana Life Sciences (TILS)

26th August, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Grant of options – Director dealings Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the board of directors of the Company (the “Board” or “Directors”), with Mr Simon and Mr Brancaccio absenting themselves on grounds of interest, has awarded the following options on 25 August…

Tiziana Life Sciences – Patent Granted on the use of Milciclib August 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

21st August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent on use…

Tiziana Life Sciences to retain Dr. Napoleone Ferrara August 20, 2020 – Posted in: Uncategorized

20th August 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term – Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech – A member of National Academy of Sciences and recipient of several prestigious awards, including the Lasker award. Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the…

Tiziana Life Sciences – Patent Granted August 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease 18 August, 2020 Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent on use and methods of treatment…

Tiziana Life Sciences (TILS) – Closing of $57.25 Million Offering August 5, 2020 – Posted in: Minexia - NR Private Market, Tiziana Life Sciences (TILS)

5th August, 2020 Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering London, New York 5 August 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its registered direct offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. As announced on 3 August 2020, Tiziana issued 11,009,615…

Tiziana Life Sciences (TILS) – Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients August 4, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tuesday 4th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients · Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety toxicity study in monkeys, and initiate a human clinical trial in COVID-19 patients This announcement contains inside information…

Tiziana Life Sciences (TILS)- Issue of Equity August 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 3rd August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million New York and London, August 3, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced it has entered into definitive agreements with investors for the purchase and sale of 11,009,615 of the Company’s American Depositary Shares…

Tiziana Life Sciences = Submission of a Patent Application for Nasal Administration of Foralumab July 31, 2020 – Posted in: Tiziana Life Sciences (TILS)

31st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients New York/London, July 31, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent…

Tiziana Life Sciences – Proposed Admission to the Official List – Posted in: Tiziana Life Sciences (TILS)

30th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Early notification of proposed admission to the Official List and cancellation of trading on AIM New York/London, 30 July 2020 – Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the “Ordinary Shares”) on the standard listing segment of the Official List of the Financial Conduct Authority (the “Official List”) and admission to trading on…

Tiziana Life Sciences – Investor Webinar July 30, 2020 – Posted in: Tiziana Life Sciences (TILS)

Thursday 30th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020 NEW YORK/LONDON, July 30, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced that Kunwar Shailubhai, Ph.D., the Company’s CEO and CSO, will share insight into…